安圖生物(603658.SH):齊齊哈爾安圖醫學檢驗實驗室取得醫療機構執業許可證
格隆匯1月15日丨安圖生物(603658.SH)公佈,公司全資子公司鄭州安圖科技發展有限公司(“安圖科技”)下屬控股子公司齊齊哈爾久和醫學檢驗有限公司(安圖科技持股比例為51%)於近日收到齊齊哈爾市衞生健康委員會簽發的《中華人民共和國醫療機構執業許可證》。
診療科目:醫學檢驗科(臨牀體液、血液專業,臨牀微生物學專業,臨牀化學檢驗專業,臨牀免疫、血清學專業)。
齊齊哈爾安圖醫學檢驗實驗室取得執業許可後,可正式開業運營,開展相關診療業務。受市場競爭、品牌推廣等多方面因素的影響,齊齊哈爾安圖醫學檢驗實驗室正式開業後對公司業績的影響存在不確定性,敬請廣大投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.